Pharmaceutical company · LLY

Eli Lilly
clinical trial
pipeline

Registry checked

Published

Metabolic/Endocrine/Nutrition is the largest mapped primary therapeutic group, with 71 of 243 active trials. This ranking covers mapped groups only. Orforglipron is linked to 17 distinct active studies, with 17 Phase 3. Brenipatide is linked to 15 distinct active studies, with 3 Phase 1, 8 Phase 2, 4 Phase 3.

Phase 3 study NCT04088396 in Systemic Juvenile Idiopathic Arthritis lists estimated primary completion in October 2026. Phase 3 study NCT04965493 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma lists estimated primary completion in October 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

243active trials
as lead sponsor
  • Phase 172
  • Phase 253
  • Phase 3101
  • Phase 411
  • Phase not recorded6

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

5639 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

02Primary completion

Primary completion moved later

2027-02 (estimated)2028-07 (estimated)
Feb 2027Jul 2028

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

NCT06297590 · ClinicalTrials.gov
Recorded by ComplyRx
30 Oct 2026
Registry last updated
29 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010200022
2026-10-022000022
2026-10-030000221
2026-10-040000000
2026-10-050000111
2026-10-061410064
2026-10-071110031
2026-10-083000033
2026-10-093000365
2026-10-101000011
2026-10-110000000
2026-10-120000000
2026-10-131000011
2026-10-140110132
2026-10-153310074
2026-10-162000353
2026-10-171000011
2026-10-180000000
2026-10-190000000
2026-10-202102054
2026-10-210000000
2026-10-221000011
2026-10-230000000
2026-10-240000000
2026-10-250000221
2026-10-260000000
2026-10-270000000
2026-10-280110132
2026-10-290000000
2026-10-300110021
Type totals211462135639 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Orforglipron

FOUNDAYO

17
Active trials
8
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 317
  • Phase 40
  • Phase not recorded0
Studied condition
Atherosclerosis Cardiovascular Disease · Behavior · Chronic Kidney Disease
Next primary completion
Feb 2027 · estimated
Open drug

Tirzepatide

Mounjaro · mounjarokwikpen · Zepbound · zepboundkwikpen

15
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 12
  • Phase 21
  • Phase 37
  • Phase 45
  • Phase not recorded0
Studied condition
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2 · Metabolic Dysfunction-Associated Steatotic Liver Disease
Next primary completion
Nov 2026 · estimated
Open drug

Brenipatide

Canonical investigational asset

15
Active trials
13
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 13
  • Phase 28
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Alcohol Use Disorder · Asthma · Bipolar Disorder
Next primary completion
Feb 2027 · estimated
Open drug

Abemaciclib

verzenio

12
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 22
  • Phase 38
  • Phase 40
  • Phase not recorded0
Studied condition
Abiraterone Acetate · Androgens · Antineoplastic Agents
Next primary completion
Feb 2027 · estimated
Open drug

Eloralintide

Canonical investigational asset

12
Active trials
9
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 16
  • Phase 20
  • Phase 36
  • Phase 40
  • Phase not recorded0
Studied condition
Cardiovascular Diseases · Diabetes Mellitus, Type 2 · End Stage Kidney Disease
Next primary completion
Not reported
Open drug

Pirtobrutinib

jaypirca

11
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 23
  • Phase 35
  • Phase 43
  • Phase not recorded0
Studied condition
B-cell Lymphoma · Chronic Lymphocytic Leukemia · Immune Thrombocytopenia (ITP)
Next primary completion
Oct 2026 · estimated
Open drug

227 of 243 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 227 of 243 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Eli Lilly trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Baricitinib

NCT04088396

Phase 3 · Active, not recruiting

Trial source and qualifications

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

Start clipped at the display horizon.

2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 12 Feb 2020 · actual
    Primary completion: Oct 2026 · estimated
    Study completion: Oct 2026 · estimated

    2021202220232024202520262027202820292030
    BRUIN CLL-322
    Pirtobrutinib

    NCT04965493

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 20 Sept 2021 · actual
      Primary completion: Oct 2026 · estimated
      Study completion: Oct 2027 · estimated

      2021202220232024202520262027202820292030
      Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
      Retatrutide

      NCT06297603

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

      3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      3 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 15 Mar 2024 · actual
        Primary completion: Oct 2026 · estimated
        Study completion: Nov 2026 · estimated

        2021202220232024202520262027202820292030
        TRIUMPH-5
        Retatrutide

        NCT06662383

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

        4 candidate observations · 1 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        3 inspected observations omitted. At most three verified observations are shown, not full history.

        • pc date moved · Recorded 2026-07-21 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 01 Nov 2024 · actual
        Primary completion: Nov 2026 · estimated
        Study completion: Dec 2026 · estimated

        2021202220232024202520262027202820292030
        SURPASS-T1D-1
        Tirzepatide

        NCT06914895

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

        2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        2 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 25 Apr 2025 · actual
          Primary completion: Nov 2026 · estimated
          Study completion: Dec 2026 · estimated

          2021202220232024202520262027202820292030
          SURPASS-T1D-2
          Tirzepatide

          NCT06962280

          Phase 3 · Active, not recruiting

          Trial source and qualifications

          A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

          2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          2 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 12 May 2025 · actual
            Primary completion: Nov 2026 · estimated
            Study completion: Jul 2027 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 109 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 38 actual primary completions, 0 untyped primary completions, 0 past estimates, 7 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            71

            active trials in Metabolic/Endocrine/Nutrition

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Metabolic/Endocrine/Nutrition71 trials
            • Oncology69 trials
            • Neurology30 trials
            • Immunology & Inflammation15 trials
            • Cardiovascular8 trials
            • Psychiatry & Addiction8 trials
            • Pain & Musculoskeletal6 trials
            • Dermatology5 trials
            • Gastroenterology & Hepatology4 trials
            • ENT & Hearing2 trials
            • Renal & Urology2 trials
            • Respiratory2 trials
            • Haematology1 trials
            • Ophthalmology1 trials
            • Unmapped4 trials
            • Healthy volunteers15 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            A

            AstraZeneca

            Shared indexed programme context · 1 selected asset

            NN

            Novo Nordisk

            Shared indexed programme context · 1 selected asset

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Enumerated controlled company group covers 2,201 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Eli Lilly and Company · Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            2,205 distinct registry candidates produced 2,201 accepted studies. 0 mapped to other owners, 4 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 2 unverified, 2 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            2,155 scoped records have indexed enrichment and 46 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-10-31T18:51:56.024Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot b499edf79097a4e1013a17c2331f83911b17d0368d9f01704e1db659a47cd172.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 2,201 mapped lead-sponsored clinical studies across all statuses. 2,155 have indexed enrichment, 46 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.